In nanomedicine, determining the
spatial distribution of particles
and drugs, together and apart, at high resolution within tissues,
remains a major challenge because each must have a different label
or detectable feature that can be observed with high sensitivity and
resolution. We prepared nanoparticles capable of enzyme-directed assembly
of particle therapeutics (EDAPT), containing an analogue of the Pt(II)-containing
drug oxaliplatin, an 15N-labeled monomer in the hydrophobic
block of the backbone of the polymer, the near-infrared dye Cy5.5,
and a peptide that is a substrate for tumor metalloproteinases in
the hydrophilic block. When these particles reach an environment rich
in tumor associated proteases, the hydrophilic peptide substrate is
cleaved, causing the particles to accumulate through a morphology
transition, locking them in the tumor extracellular matrix. To evaluate
the distribution of drug and EDAPT carrier in vivo, the localization of the isotopically labeled polymer backbone was
compared to that of Pt by nanoscale secondary ion mass spectrometry
(NanoSIMS). The correlation of NanoSIMS with super-resolution fluorescence
microscopy revealed the release of the drug from the nanocarrier and
colocalization with cellular DNA within tumor tissue. The results
confirmed the dependence of particle accumulation and Pt(II) drug
delivery on the presence of a Matrix Metalloproteinase (MMP) substrate
and demonstrated antitumor activity. We conclude that these techniques
are powerful for the elucidation of the localization of cargo and
carrier, and enable a high-resolution assessment of their performance
following in vivo delivery.